Showing 1391-1400 of 1717 results for "".
- FDA Approves Ingrezza Sprinkle Formulation for Tardive Dyskinesia or Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/fda-approves-ingrezza-sprinkle-formulation-for-tardive-dyskinesia-or-chorea-associated-with-huntington-disease/2470463/The Food and Drug Administration (FDA) has approved a new sprinkle formulation of Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) for patients with tardive dyskinesia (TD) or chorea associated with Huntington disease (HD). The oral granule capsules (available in 40 mg, 60 mg, and 80
- Treatment of Focal Epilepsy with Cenobamate Associated with Lower Inpatient Days and ER Visits Compared with 7 Leading Anti-Seizure Medicationshttps://practicalneurology.com/news/treatment-of-focal-epilepsy-with-cenobamate-associated-with-lower-inpatient-days-and-er-visits-compared-with-7-leading-anti-seizure-medications/2470448/The addition of cenobamate to the treatment regimens of people with focal epilepsy was associated with lower rates of inpatient days and emergency room (ER) visits compared with the addition of 7 other leading anti-seizure medications (ASMs). This finding, which was presented at the American Acad
- New Partnership Between myTomorrows and the ALS Association Aims to Expand Clinical Trial Participationhttps://practicalneurology.com/news/new-partnership-between-mytomorrows-and-the-als-association-aims-to-expand-clinical-trial-participation/2470426/The global health technology company myTomorrows has announced a new partnership with the ALS Association, a US nonprofit organization working to combat amyotrophic lateral sclerosis (ALS) through research, governmental partnerships, and coordinating care and assistance for people with ALS. This
- Large-Scale Study in The Lancet Neurology Documents Demographic, Clinical, and Biomarker Features Associated with Posterior Cortical Atrophyhttps://practicalneurology.com/news/large-scale-study-in-the-lancet-neurology-documents-demographic-clinical-features-and-biomarkers-associated-with-posterior-cortical-atrophy/2470389/Findings from a large-scaled research study published in The Lancet Neurology, provide new insight into the demographic characteristics of posterior cortical atrophy (PCA), which is a rare syndrome associated with the underlying neuropathologic features of Alzheimer disease (AD). Accordi
- Botulinum Toxin A Treatment Associated with Improvements in Essential and Isolated Head Tremor According to Results from RCThttps://practicalneurology.com/news/botulinum-toxin-a-treatment-associated-with-improvements-in-essential-and-isolated-head-tremor-according-to-results-from-rct/2470365/Injection of botulinum toxin A into the splenius capitis muscle was associated with reductions in the severity of essential and isolated head tremor, according to results from a randomized clinical trial published in The New England Journal of Medicine. Secondary outcome measures from th
- Lumryz Treatment Associated with Significant Improvements in Mean Sleep Latency According to REST-ON Studyhttps://practicalneurology.com/news/lumryz-treatment-associated-with-significant-improvements-in-mean-sleep-latency-according-to-rest-on-study/2470322/Use of once-nightly (ON) Lumryz (sodium oxybate; Avadel Pharmaceuticals, Dublin, Ireland) was associated with clinically significant improvements in mean sleep latency compared with placebo according to a presentation at the World Sleep 2023 Congress. The results were from a post hoc analysis of
- Indirect Treatment Comparison Between Ingrezza and Austedo to Treat Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/indirect-treatment-comparison-between-ingrezza-and-autesto-to-treat-chorea-associated-with-huntington-disease/2470278/Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) may provide more benefit in early treatment of chorea symptoms associated with Huntington disease (HD) than Austedo (deutetrabenazine; Teva Pharmaceuticals, Tel Aviv, Israel), according to results of a study presented at the 2023 Inter
- Large Scandinavian Study Finds Many Antiseizure Medications Associated with Low Birth Weight in Infantshttps://practicalneurology.com/news/large-scandanavian-study-finds-many-antiseizure-medications-associated-with-low-birth-weight-in-infants/2470078/Results from the largest study to date on antiseizure medications and birth weight presented at the American Epilepsy Society Annual Meeting reveal that lamotrigine was not associated with either birth defects or low birth weight. Other agents studied, such as carbamazepine, oxcarbazepine, and to
- Muscular Dystrophy Association and Magic Wheelchair Launch 2022 Halloween Costume Competition to Raise Neuromuscular Disease Awarenesshttps://practicalneurology.com/news/muscular-dystrophy-association-and-magic-wheelchair-launch-2022-halloween-costume-competition-to-raise-neuromuscular-disease-awareness/2469729/The Muscular Dystrophy Association (MDA) and Magic Wheelchair have launched a Instagram competition to win a Magic Wheelchair Halloween costume in 2022. To enter, participants with neuromuscular diseases need to follow@MDAorg and @MagicWheelchair on Instagram and comment with a purple heart on al
- First Doses Given in Clinical Trial of Antisense Oligonucleotide for C9orf72-Associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementiahttps://practicalneurology.com/news/first-doses-given-in-clinical-trial-of-antisense-oligonucleotide-for-emc9orf72em-associated-amyotrophic-lateral-sclerosis-and-frontotemporal-dementia/2469640/Multiple participants have had initial doses of an antisense oligonucleotide (ASO) (WVE-004; Wave Life Sciences, Cambridge, MA) being evaluated for treatment of C9orf72-associated amyotrophic lateral sclerosis (C9-ALS) and frontotemporal dementia (C9-FTD). This ASO is designed to